NCT02135042 2026-03-18
Individualized Treatment in Treating Patients With Stage II-IVB Nasopharyngeal Cancer Based on EBV DNA
NRG Oncology
Phase 2/3 Active not recruiting
Clinical Trials
59 trialsNCT07368634 2026-01-28
Exploratory Study of EBV-TCR-T Cell Injection for EBV DNAemia After Allogeneic Hematopoietic Stem Cell Transplantation
Chinese PLA General Hospital
Phase 1/2 Recruiting
NCT07368153 2026-01-26
IDEP
University Hospital, Basel, Switzerland
Phase 2 Not yet recruiting
NCT07294547 2025-12-19
Is Valacyclovir Non-inferior to Valganciclovir as CMV and EBV Prophylaxis in Kidney Transplant Recipients? A Single-Center Prospective Randomized Pilot Study
National Taiwan University Hospital
Phase NA Recruiting
NCT02048332 2025-12-16
VSTs
Children's Hospital Medical Center, Cincinnati
Phase 1/2 Recruiting
NCT04664179 2025-12-12
CILESTE
Baylor College of Medicine
Phase 1 Recruiting
NCT07261215 2025-12-03
Zuberitamab for EBV Infection Post-Allo-HSCT
Institute of Hematology & Blood Diseases Hospital, China
Phase 2 Not yet recruiting
NCT04925544 2025-10-21
Novel Small Molecule EBNA1 Inhibitor, VK 2019, in Patients With Epstein Barr Virus (EBV)-Positive Nasopharyngeal Cancer (NPC) and Other Epstein-Barr Virus (EBV)-Associated Cancers, With Pharmacokinetic and Pharmacodynamic Correlative Studies
Stanford University
Phase 2 Active not recruiting
NCT07138989 2025-08-24
EBV Lytic Reactivation Therapy Combined With PD-1 Antibody in Recurrent/Metastatic Nasopharyngeal Carcinoma
Sun Yat-sen University
Phase 2 Not yet recruiting
NCT07133776 2025-08-21
Application of PD-1 Inhibitors Combined With Tenofovir, Chidamide and Lenalidomide in the Treatment of EBV-associated Diseases.
The Affiliated Hospital of Xuzhou Medical University
Phase 1/2 Not yet recruiting
NCT02363400 2025-08-19
A Phase III Trial in NPC With Post-radiation Detectable Plasma EBV DNA
National Health Research Institutes, Taiwan
Phase 3 Terminated
NCT06909110 2025-08-14
Viral Specific T-Lymphocytes to Treat Infection With Adenovirus, Cytomegalovirus or Epstein-Barr Virus in Patients With Compromised Immunity
Stanford University
Phase 1/2 Recruiting
NCT03266653 2025-08-08
EBV-specific Cytotoxic T-lymphocytes (CTLs) for Refractory EBV Infection
New York Medical College
Phase 2 Recruiting
NCT04013802 2025-08-08
TETRAVI
Baylor College of Medicine
Phase 1 Recruiting
NCT06926894 2025-07-31
R-MVST Cells for Treatment of Viral Infections in Children and Young Adults
Columbia University
Phase 1 Recruiting
NCT04832607 2025-07-18
TRACE
University Hospital Freiburg
Phase 3 Recruiting
NCT01494103 2025-07-11
DOTTI
Baylor College of Medicine
Phase 1 Active not recruiting
NCT06027879 2025-06-25
Gamma Capture
University of Pittsburgh
Phase 1/2 Enrolling by invitation
NCT02580539 2025-05-14
EBV-TCL-01
Maisonneuve-Rosemont Hospital
Phase 1/2 Completed
NCT03475212 2025-05-11
ACES
Pediatric Transplantation & Cellular Therapy Consortium
Phase 1/2 Active not recruiting
NCT06682442 2025-04-20
Induction Chemotherapy Response-Guided Radiation for EBV-Associated Nasopharyngeal Carcinoma
University of California, San Francisco
Phase NA Recruiting
NCT06870435 2025-03-11
Comparison and Strategy Optimization of Plasma EBV DNA and P85-Ab with VCA/EBNA1-IgA for Screening Nasopharyngeal Carcinoma in High-risk Areas
Sun Yat-sen University
Phase NA Recruiting
NCT05688241 2025-03-03
ESPECT
University Hospital, Basel, Switzerland
Phase 1/2 Not yet recruiting
NCT05183490 2024-12-30
R-MVST Cells for Treatment of Viral Infections
Columbia University
Phase 1 Recruiting
NCT03813394 2024-11-22
2018/00947
National University Hospital, Singapore
Phase 1/2 Active not recruiting
NCT02875613 2024-08-28
Avelumab for Recurrent/Metastatic Nasopharyngeal Cancer
University of California, San Diego
Phase 2 Terminated
NCT06224049 2024-03-12
GI-hNeoT-01
BGI, China
Phase EARLY_PHASE1 Recruiting
NCT06119256 2023-11-07
Clinical Study of EBV-TCR-T Cells for EBV Infection After Allogenic HSCT
Chinese PLA General Hospital
Phase 1 Recruiting
NCT06075927 2023-10-10
Multivirus-specific T Cells in the Treatment of Refractory CMV and/or EBV Infection After Allo-HSCT
Peking University People's Hospital
Phase 1/2 Unknown
NCT00834093 2023-06-28
A Phase II Study of Epstein-Barr Virus-Specific Immunotherapy for Nasopharyngeal Carcinoma
Dana-Farber Cancer Institute
Phase 2 Completed
NCT05775705 2023-03-20
L-DEP Regimen Combined With PD-1 Antibody as Induction Therapy for Epstein-Barr Virus-positive LA-HLH
Beijing Friendship Hospital
Phase 3 Not yet recruiting
NCT04507477 2022-08-02
Ex-vivo Delivery of Rituximab to Prevent PTLD in EBV Mismatch Lung Transplant Recipients: A Pilot Trial
University Health Network, Toronto
Phase 1/2 Unknown
NCT00478465 2022-05-27
Valganciclovir (Valcyte) for Chronic Fatigue Syndrome Patients Who Have Elevated Antibody Titers Against Human Herpes Virus 6 (HHV-6)and Epstein-Barr Virus (EBV)
Stanford University
Phase 1/2 Completed
NCT01972035 2022-04-12
ValGanciclovir Versus ValAcyclovir for Viral Prophylaxis in Kidney Transplantation
University of Minnesota
Phase 2 Completed
NCT02499302 2022-02-16
Mental Training for CFS Following EBV Infection in Adolescents
University Hospital, Akershus
Phase NA Completed
NCT02874651 2022-01-11
ADVANCE
Sun Yat-sen University
Phase 2 Terminated
NCT04084626 2022-01-05
PD1 Antibody and Lenalidomide as a Treatment for EBV-HLH or CAEBV
Beijing Friendship Hospital
Phase 3 Unknown
NCT01535885 2021-10-25
ACE
Medical College of Wisconsin
Phase 1 Completed
NCT05039580 2021-09-09
SEHC
The First Affiliated Hospital of Soochow University
Phase 4 Unknown
NCT01094405 2021-07-28
Efficacy of Recombinant Epstein-Barr Virus (EBV) Vaccine in Patients With Nasopharyngeal Cancer Who Had Residual EBV DNA Load After Conventional Therapy
Chinese University of Hong Kong
Phase 2 Completed
NCT04690036 2021-06-29
PD-1 Antibody for Reactive EBV After BMT
Beijing Friendship Hospital
Phase EARLY_PHASE1 Unknown
NCT02227641 2020-12-14
Preventative/Preemptive Adoptive Transfer of Peptide Stimulated CMV/EBV Specific T-cells in Patients After Allogeneic Stem Cell Transplantation
University of Erlangen-Nürnberg Medical School
Phase 1/2 Completed
NCT00058591 2020-01-18
SCAEBV
Baylor College of Medicine
Phase 1 Completed
NCT01964755 2019-09-23
Chemotherapy for Relapsed Epstein Barr Virus Associated Lymphoma
University of Miami
Phase 2 Terminated
NCT03159364 2019-09-19
Antigen-specific Cytotoxic T Cells in the Treatment of Opportunistic Infections
Shenzhen Geno-Immune Medical Institute
Phase 1/2 Unknown
NCT01800071 2018-07-17
A Phase Ib Trial of MVA-EBNA1/LMP2 Vaccine in Nasopharyngeal Carcinoma
Cancer Research UK
Phase 1 Completed
NCT01058239 2018-02-15
Bortezomib Plus Rituximab for EBV+ PTLD
Massachusetts General Hospital
Phase 2 Completed
NCT00953420 2017-08-18
CADEN
Baylor College of Medicine
Phase 2 Completed
NCT02912702 2016-09-23
L-DEP as an Initial Treatment for EBV-HLH
Beijing Friendship Hospital
Phase 3 Unknown
NCT02631109 2016-08-04
L-DEP Regimen as a Salvage Therapy for Refractory Epstein Barr Virus-induced Hemophagocytic Lymphohistiocytosis
Beijing Friendship Hospital
Phase 3 Unknown